INTRODUCTION
Biliary atresia is a congenital, fibroobliterative obstructive cholangiopathy. Biliary atresia is the most common cause of pathologic direct hyperbilirubinemia [1] [2] [3] . Timely diagnosis for intervention of the disease is critical because of the rapid progression toward cirrhosis [2, [4] [5] [6] . Unfortunately, surgical drainage, the only effective intervention, is successful only half of the time [1, 5, 6] . As such, biliary atresia is the most common cause of endstage liver disease and the leading indication for liver transplantation in children [4] . Ultimately, approximately 80% of children with biliary atresia will require one or more liver transplantations with the associated morbidity and mortality issues caused by life-long transplant-related immunosuppression [7] [8] [9] [10] [11] . Herein, we review recent advances in the understanding and management of biliary atresia.
PATHOGENESIS OF BILIARY ATRESIA
One prominent theory regarding the pathogenesis is that bile duct injury is initially caused by a viral infection, as originally proposed by Landing [12] , and then perpetuated by an autoimmune disorder.
Using the established, experimental model of biliary atresia caused by perinatal inoculation of BALB/c mouse pups with Rhesus rotavirus (RRV) [13] , Mohanty et al. [3] recently demonstrated the dependence of biliary destruction on rotavirus replication in cholangiocytes. Hertel et al. observed that passively acquired serum antibody against RRV attenuates viral replication. The authors further demonstrated that the antibody is protective against RRV-induced biliary atresia and that early viral clearance is likely a critical determinant of the disease [14, 15] . Nakashima et al. [14] reported that hepatobiliary pathology with inoculation of DBA/1J mouse pups with Reovirus-2 mimicks that of human biliary atresia as well as RRV-induced biliary atresia. Past studies demonstrated the role of T-cell, B-cell, and natural killer (NK) cells in the immunologic destruction of the extrahepatic bile duct, in part mediated by interferon-g, interleukin-2, tumor necrosis factor-a, and interleukin-12 [16] . Brindley et al. [17] showed a robust hepatic T-cell memory with significant increase in interferon-g in response to cytomegalovirus exposure, suggesting that perinatal cytomegalovirus exposure may be a possible initiator to biliary atresia. Feldman et al. [18] recently showed that B-cell-deficient mice are protected from biliary obstruction in RRV-induced biliary atresia, further validating the role of B cells in biliary atresia pathogenesis. This may involve lack of B-cell antigen presentation and consequently impaired T-cell activation and Th1 inflammation [18] . Okamura et al. [19] found that CD56 À CD16 þ CD68 À NK cells were increased in damaged biliary atresia bile ducts. The authors also showed that these CD16 þ NK cells express CX3CR1, which homes them to CX3CL1 expressed by biliary epithelium. In cultured biliary epithelial cells, CX3CL1 expression can be stimulated by Toll-like receptor activation using a doublestranded RNA analog. Qiu et al. [20] demonstrated that a susceptibility to experimental RRV-induced biliary atresia may be in part due to immaturity of NK cell responsiveness and clearance of RRV infection of cholangiocytes. Okamura et al. [21] demonstrated induction of expression of the proinflammatory cytokine interleukin-32, which is present in the damaged bile ducts of patients with biliary atresia, is induced in cultured biliary epithelial cells by synthetic viral double-stranded RNA via toll-like receptor activation, interferon-g, and tumor necrosis factor-a.
Suskind et al. [22] originally described the presence of maternal microchimerism in the livers of infants with biliary atresia suggesting a potential alloautoimmune basis for the immune dysfunction seen in biliary atresia. Muraji et al. subsequently identified maternal chimeric CD8 þ T cells in the livers of infants with biliary atresia [23, 24] . Interestingly, Nijagal et al. [25] identified lower rates of graft failure and retransplantation in recipients with biliary atresia who received maternal donor liver compared with those who received paternal donor liver, suggesting the possibility of immune tolerance secondary to exposure to noninherited maternal antigens. Muraji [23] recently summarized findings over the past decade regarding the theory that maternal microchimerism is the underlying cause of biliary atresia wherein the initial biliary hit is due to graft-versus-host interaction by engrafted maternal effector T lymphocytes. Ongoing analyses are essential to validate this mechanism of disease.
There continue to be notable reports of genetic polymorphisms that may predispose patients to biliary atresia. Leyva-Vega et al. [26] identified single-nucleotide polymorphisms in the 2q37.3 region associated with biliary atresia indicating that genes within this region may confer susceptibility to biliary atresia. Using genome-wide association studies of copy number variants to identify susceptibility loci in 61 patients with biliary atresia, Cui et al. [27] recently characterized a cluster of deletions at 2q37.3 that result in deletion of one copy of GPC1, which encodes glypican-1, a heparan sulfate proteoglycan that regulates Hedgehog signaling and inflammation. Additional functional analyses including morpholino knockdown of gpc1 in zebrafish demonstrated a role for Hedgehog signaling in the pathogenesis of biliary atresia. Following initial genome-wide association studies, which linked mutations within the 10q24.2 locus to biliary atresia in the Han Chinese population [28] , more recent analyses identified that common genetic variants in the ADDUCIN-3 gene increased the risk of developing biliary atresia [29] .
The rapidly progressing biliary fibrosis associated with biliary atresia impacts outcomes of infants with biliary atresia in terms of survival with one's native liver [1] . The principal cellular origins of collagenproducing myofibroblasts are hepatic stellate cells and portal fibroblasts [30] . Dranoff and Wells [31] characterized isolated portal fibroblasts to demonstrate their role in a mouse model of biliary fibrosis induced by bile duct ligation. Iwaisako et al. [32] recently demonstrated via cell lineage tracing studies that portal fibroblasts are the predominant precursor of myofibroblasts in bile duct ligation-induced biliary
KEY POINTS
Genetic mutations may impact biliary organogenesis and contribute to the biliary atresia phenotype.
Innate immunity may contribute to the destruction of the biliary epithelium that occurs in biliary atresia.
An expanding population of cells expressing progenitor/stem cell markers within and adjacent to ductular reactions within evolving regions of biliary fibrosis may contribute to the pool of activated portal fibroblasts.
Newborn screening of infants may improve outcomes of infants with biliary atresia and be associated with a cost benefit.
Corticosteroid therapy following portoenterostomy does not improve survival with a native liver and is associated with earlier onset of adverse side-effect.
fibrosis.
A key pathologic intrahepatic finding of biliary atresia, which distinguishes it from other nonbiliary causes of liver fibrosis, is the presence of proliferating ductular reactions or biliary hyperplasia. These ductular reactions are typically present within regions of bridging fibrosis, suggesting a potential role of these cells in the fibrogenesis of biliary atresia. These ductular reactive cells share common characteristics with epithelial progenitor and stem cells [33] [34] [35] [36] . Immunohistochemical analyses indicate that these ductular reactive cells also express both epithelial and mesenchymal markers, which has led some investigators to speculate that these ductular epithelial cells may be undergoing transdifferentiation into collagen-producing mesenchymal cells [37, 38] . However, others refute the phenomenon of hepatic epithelial-mesenchymal transition [39] [40] [41] . Within regions of developing biliary atresiaassociated biliary fibrosis in both RRV-induced biliary atresia and human biliary atresia, there is expansion of a population of cells within and adjacent to ductular reactions, expressing the progenitor/stem cell marker prominin-1 along with numerous epithelial and mesenchymal markers [42 & ]. PROM1-expressing dual epithelial-mesenchymal cells also coexpress Collagen-1a and, therefore, may contribute to the pool of portal fibroblasts.
MANAGEMENT OF BILIARY ATRESIA
The only effective treatment for biliary atresia is the hepatoportoenterostomy (HPE) originally described by Morio Kasai in 1959 [43, 44] . This operation involves excision of the extrahepatic biliary remnant with a high portal-plate dissection in order to maximize exposure of residual bile ductules. Drainage of bile is reestablished from the portal plate into a 40-50 cm Roux limb of jejunum [45] Overall, standard open Kasai is associated with jaundice clearance in 47-65% of infants, and successful biliary drainage is manifested in the stool color usually within the first postoperative week [46] [47] [48] . A serum direct bilirubin of less than 2.0 mg/dl within 3 months post-Kasai is highly predictive of survival with one's native liver [1] .
Given the modest success rates of achieving surgical biliary drainage, efforts to improve the outcomes of biliary atresia infants span multiple levels of clinical investigation. Institutional case volume is a positive predictor of outcome for a number of complex operations [49] [50] [51] [52] . McKiernan et al. [53] reported outcomes of infants with biliary atresia undergoing HPE in the United Kingdom and Ireland during a 2-year period. The authors reported higher rates of clearance of jaundice odds ratio 2.02 and 5-year survival without transplantation 61 vs. 13% in high-volume centers managing more than five cases per year compared with low-volume centers. These findings ultimately lead to a national directive to centralize biliary atresia management in England and Wales [54] . Davenport et al. [55] subsequently reported national outcome measures for biliary atresia, which demonstrated improved native liver and overall survival rates following HPE compared with comparable countries, that the authors attributed to centralization of care [55] . Serinet et al. [56] reported the French experience wherein they observed a similarly increased native liver survival in centers with higher volume three or more HPE per year compared with lower volume centers two or fewer HPE per year. In contrast, Shreiber et al. [57] did not observe any improvement in post-HPE survival with native liver with higher center case volume in Canada.
As earlier treatment predicts successful surgical drainage, earlier diagnosis is an important goal in efforts to significantly impact outcomes of infants with biliary atresia [1] . Prenatal or newborn screening is not routine, but there is evidence of the potential benefit of screening. Harpavat et al. [58] retrospectively demonstrated that 100% of infants with biliary atresia who had serum bilirubin levels determined shortly after birth exhibited both total and direct hyperbilirubinemia. This suggests that serum bilirubin levels could potentially be used as a method of screening for biliary atresia. In Taiwan, where the incidence of biliary atresia is high, a universal screening program has been active since 2004 [59] . Parents of all newborns are given color cards that show the spectrum of normal green stool to abnormal pale stool with the instructions to check the stool routinely and notify their pediatricians if abnormal colored acholic stool is seen. Positive results from screening resulted in additional diagnostic work-up. With Taiwanese infants, the stool color card screening program had a sensitivity of 89.7%, a specificity of 99.9%, a positive predictive value of 28.6%, and a negative predictive value of 99.9% for identification of biliary atresia [60] In subsequent analyses, the authors concluded that the implementation of this program led to earlier diagnosis and earlier HPE 66 vs. 49% at less than 60 days of age, as well as improved 3-year jaundice-free survival 57 vs. 31.5% compared with a cohort of historical controls [59, 61] . More recently, these observations were extrapolated to two North American populations utilizing cost-effectiveness modeling [62,63 & ]. Both studies demonstrated significant gains in life-years as well as decreased cost of care.
Given the evidence that biliary atresia is an inflammatory and potentially an autoimmune disease, immunosuppression is a logical modality of treatment of biliary atresia as it is effective for other inflammatory or autoimmune diseases [64, 65] . However, results from postoperative corticosteroid use for biliary atresia use have been variable. Although a number of small, nonrandomized, retrospective reports demonstrated promising improvements in biliary drainage and transplantfree survival with corticosteroids, others studies did not [66] [67] [68] [69] [70] [71] [72] [73] [74] . Davenport et al. [75] reported a singlecenter prospective, nonblinded trial, wherein a significant reduction in serum bilirubin was observed with post-HPE corticosteroid treatment but transplant-free survival was not improved. A prospective, randomized trial in Japan did not demonstrate an improvement in serum bilirubin with post-HPE corticosteroids [48] . Recently, the National Institutes of Health-funded Childhood Liver Disease Research Network (ChiLDReN) reported that their prospective, randomized, double-blinded, placebo-controlled trial of high-dose steroids in 140 patients with post-HPE therapy did not demonstrate a statistically significant difference in drainage at 6 months or transplant-free survival, although the authors noted that a small clinical benefit could not be ruled out. Importantly, steroid treatment was associated with earlier onset of serious adverse events [76 && ]. Immunoglobulin G (IgG) therapy has been used effectively for a number of inflammatory and autoimmune disorders including neonatal hemochromatosis [77] . Hence, it has been theorized that highdose IgG therapy, which reduces secretion of proinflammatory cytokines and increase the number of anti-inflammatory regulatory T cells in other autoimmune diseases [78] , might be efficacious in biliary atresia in lieu of corticosteroids. Fenner et al. [79 & ] studied the effects of high-dose IgG in experimental biliary atresia in mouse pups and observed a decreased bilirubin, peribiliary inflammation, and increased ductal patency. The authors further observed a decrease in vascular cell adhesion molecule-1 expression, with reduced migration of immune cells to portal tracts. Importantly, highdose IgG also significantly decreased CD4 þ and CD8 þ T-cell production of proinflammatory cytokines and increased levels of anti-inflammatory regulatory T cells. At present, ChiLDReN is enrolling patients into a Food and Drug Administrationapproved phase 1/2a clinical trial to study the safety and efficacy profiles of intravenous immunoglobulin treatment administered to infants after portoenterostomy for biliary atresia (https://clinicaltrials.gov/ct2/show/NCT01854827).
Recurrent cholangitis, which is thought to be the consequence of ascending bacteria colonization up the roux limb toward the portal plate, is a significant issue for most infants with biliary atresia following portoenterostomy. Lee et al. [1] determined that 27 (64.3%) of 42 children experienced an average of 3.6 episodes of cholangitis with a mean length of stay of 2 weeks. Common organisms in blood culture isolates in their study included Klebsiella pneumoniae, Enterococcus, Escherichia coli, and Pseudomonas aeruginosa. Lien et al. [80] recently reported a pilot study in which 20 jaundice-free patients with biliary atresia were prospectively randomized to receive either prophylactic neomycin or lactobacillus. Both groups experienced equivalent rates of cholangitis, which were lower than historic nontreated controls, suggesting the potential efficacy of lactobacillus in preventing cholangitis. Shneider et al. [81] reported clinically definable portal hypertension in two-thirds of 163 prospectively followed North American long-term survivors with native liver. Biochemical evidence of fatsoluble vitamin insufficiency is common among infants with biliary atresia despite supplementation [81] . Over 98% of patients with biliary atresia surviving more than 5 years with their native liver after portoenterostomy exhibit either clinical or biochemical evidence of chronic liver disease [82] . A study pooling 162 patients from 14 published articles, who had survived with their native liver for more than 20 years, reported that 88% (162/184) were still alive with their native liver and that 60% were experiencing liver-related complications [83] . Nonetheless, survey data of patients with biliary atresia surviving with their native livers indicate that their health statuses and quality of life are similar to those of their healthy peers [84] .
CONCLUSION
Biliary atresia remains an incompletely solved puzzle. There have, however, been strides in determining the underlying pathogenesis of this neonatal fibrosing cholangiopathy. Moreover, the evolution of clinical care continues with a greater focus on newborn screening and suppression of the immune dysregulation associated with biliary atresia.
